WILMINGTON, Del.—May 21, 2018—Life sciences companies can – for the first time – access one of the largest commercially insured population databases in the United States and find answers faster and more cost-effectively to questions, including whether they’re targeting the right populations for clinical trials, with the launch of HealthCore’s integrated database through Boston Health Economics’ Instant Health Data platform.
Access to the HealthCore Integrated Research Database, known as the HIRD,contains integrated longitudinal medical and pharmacy claims data for more than 48 million individuals and lab result data for more than 17 million individuals. The HIRD provides researchers with improved healthcare insights and decision making through an easy-to-use software interface by allowing them to answer questions about how their products fit into treatment patterns, whether their products impact the correct population and whether their targeted clinical trial group will lead to meaningful and actionable findings.
“Researchers using the HIRD and the Boston Health Economics platform now have the ability to create a code definition library, identify specific population groups, specify baseline and outcome variables, conduct statistical analyses, and produce reports – all in an easy-to-use interface,” said Mark Cziraky, vice president of research for HealthCore. “Ultimately, this unique combination of the HIRD and Boston Health Economics’ Instant Health Data Platform will enable our clients to improve insights and decision making in healthcare.”
Researchers can use the HIRD to rapidly conduct end-to-end investigations on de-identified data from patients using products in the real world, not in a clinical trial setting. Researchers are able to characterize patient populations, conduct feasibility assessments, optimize trial and other research designs, identify a product’s place in the treatment paradigm, assess unmet need, and perform complex comparative safety and efficacy analyses.
“We are excited to bring the HIRD database to our customers for the very first time, opening up new possibilities for gaining insights from this large, rich patient population using the most widely-adopted real-world data analytics platform,” said Joseph Menzin, founder and CEO of Boston Health Economics.
When the research design requires going beyond de-identified claims data, the HealthCore team will have the ability to use its broader HealthCore Integrated Research Environment on the same group of patients and physicians defined by the Instant Health Data researcher. This will enable clients to conduct focus groups and surveys with patients and providers, include more detailed resource use and cost of care analysis, perform clinical record review and validation, and design and implement site-based observational studies and pragmatic clinical trials.
HealthCore, Inc. is the wholly-owned, independently operating health outcomes research subsidiary of Anthem, Inc. We work with life sciences companies, payers and providers, and government and academic organizations to provide real-world evidence in support of a wide variety of health care decisions. Our research capabilities include extensive experience in HEOR, Late Phase, Safety and Epidemiology and Survey-Based research services and solutions with our work designed to improve quality, safety and affordability in health care. With more than 20 years of experience, clinical and scientific research expertise, and exclusive access to a robust, integrated research environment containing information on nearly 60 million individuals from multiple health plans across the U.S., HealthCore delivers unparalleled clarity and actionable information to health care decision makers. To learn more about HealthCore, go to www.healthcore.com.
About Boston Health Economics
BHE is an independent health analytics company with over two decades of experience in designing and conducting research that assesses the value of medical technologies. We enable analytic teams from diverse disciplines to generate evidence on how medical advances can improve patients’ health in an affordable way.